ACAD vs SGRY
ACADIA Pharmaceuticals Inc. vs Surgery Partners, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
SGRY
Surgery Partners, Inc.
48
Watch
| Metric | ACAD | SGRY |
|---|
| AI Score |
69
|
48
|
| Price |
$29.41
|
$15.02
|
| P/E Ratio |
13.07×
|
-21.74×
|
| ROE |
31.9%
|
-4.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
21.4%
|
| Debt / Equity |
0.06×
|
2.40×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
42.3
|
| Beta |
0.845
|
1.937
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus SGRY.
ACAD leads by 21 points.
ACAD scores 69/100 (Buy) versus SGRY at 48/100 (Watch).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
SGRY Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -20.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price-to-book of 1.2x is a discount to asset value — Value
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- ROE of only -4.6% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.16 adds balance-sheet risk to the value case — Value
- Revenue declining -20.5% YoY -- this is not a growth story right now — Growth